Le Lézard
Classified in: Health, Business
Subject: ATY

Bernstein Liebhard LLP Partner Named to Plaintiffs' Executive Committee for Federal Onglyza Heart Failure Lawsuits


NEW YORK, Sept. 20, 2018 /PRNewswire/ -- Daniel C. Burke, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices, has been appointed to the Plaintiffs' Executive Committee in the multidistrict litigation established earlier this year for all federally-filed product liability lawsuits involving Onglyza and Kombiglyze XR.

Bernstein Liebhard LLP.  (PRNewsFoto/Bernstein Liebhard LLP) (PRNewsfoto/Bernstein Liebhard LLP)

According to an Order issued by the U.S. District Court, Eastern District of Kentucky, on September 4th, Mr. Burke and his fellow committee members will work closely with Plaintiffs' Co-Lead and Liaison Counsel to coordinate case management of the proceeding.  (IN RE: ONGLYZA (SAXAGLIPTIN) AND KOMBIGLYZE XR (SAXAGLIPTIN AND METFORMIN) PRODUCTS LIABILITY LITIGATION, MDL No. 2809)

"Our Firm is representing numerous clients who developed heart failure and other cardiovascular complications, allegedly as a result of exposure to saxagliptin, the active ingredient in Onglyza and Kombiglyze XR. We are pleased that Mr. Burke will be playing such an integral role in this litigation," says Sandy A. Liebhard, a founding partner at Bernstein Liebhard LLP.

The Firm continues to offer free legal reviews to individuals who were diagnosed with heart failure or other cardiovascular injuries following treatment with Onglyza or Kombiglyze XR.

Onglyza Litigation
Onglyza and Kombiglyze XR are indicated to lower blood sugar levels in patients with Type 2 diabetes. The U.S. Food & Drug Administration (FDA) approved Onglyza (saxagliptin) in 2009. Kombiglyze XR, (saxagliptin and metformin) was approved the following year.

In April 2016, the FDA ordered the manufacturers of Onglyza and Kombiglyze XR to add warnings regarding a potential risk of heart failure to the labels of all saxagliptin-containing Type 2 diabetes drugs. The agency acted after a clinical trial called SAVOR-TMI suggested that saxagliptin was associated with a 27% increase in hospitalizations for heart failure, as well as a higher risk of all-cause mortality.

More than 200 Onglyza and Kombiglyze XR lawsuits are now pending in the federal multidistrict litigation underway in Kentucky. Plaintiffs involved in this proceeding claim that AstraZeneca and Bristol-Myers Squibb concealed information linking saxagliptin to an increased risk of heart failure and failed to warn doctors and patients about its alleged potential to cause cardiac arrest, congestive heart failure, and death.

Type 2 diabetics who developed heart failure or other serious cardiovascular complications allegedly related to their use of Onglyza or Kombiglyze XR could be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To contact an attorney and obtain a free case evaluation, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP  
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP 
10 East 40th Street 
New York, New York 10016 
800-511-5092

ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information: 
Sandy A. Liebhard, Esq. 
Bernstein Liebhard LLP 
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/  
https://plus.google.com/115936073311125306742?rel=author

 

SOURCE Bernstein Liebhard LLP


These press releases may also interest you

at 07:15
Fiserv, Inc. , a leading global provider of payments and financial services technology solutions, today reported financial results for the first quarter of 2024. First Quarter 2024 GAAP Results GAAP revenue for the company increased 7% to $4.88...

at 07:15
BlackSky Technology Inc. will host a conference call to discuss first quarter 2024 financial results and its business outlook on Wednesday, May 8, 2024, at 8:30 a.m. EDT. A press release with BlackSky's financial results will be released in advance...

at 07:10
908 Devices Inc. , a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. Company management will...

at 07:10
Montrose Environmental Group, Inc. (the "Company," "Montrose" or "MEG") announced today that it will issue its first quarter 2024 earnings release on Tuesday, May 7, 2024, after the close of trading on the New York Stock Exchange. You are invited...

at 07:10
Rockwell Automation, Inc. is scheduled to report its second quarter fiscal 2024 results on Tuesday, May 7, before the market opens. The release will be posted on the Rockwell Investor Relations website at...

at 07:07
Greenwave Technology Solutions, Inc. ("Greenwave" or the "Company") , a leading operator of metal recycling facilities in Virginia, North Carolina, and Ohio, announced today that on April 22, 2024, it further strengthened...



News published on and distributed by: